The Zacks Analyst Blog Highlights: General Electric, Walt Disney, Merck, Pfizer and Chevron

For Immediate Release

Chicago, IL – June 05, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include General Electric Company (NYSE: GE – Free Report ), Walt Disney Company (NYSE: DIS – Free Report ), Merck & Co., Inc. (NYSE: MRK – Free Report ), Pfizer, Inc. (NYSE: PFE – Free Report ) and Chevron (NYSE: CVX – Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Monday’s Analyst Blog:

Dow 30 Stock Roundup: GE, MRK & More

The Dow suffered across the holiday shortened week, buoyed only by encouraging private sector hiring. After remaining closed on Monday for a holiday, the index slipped on Tuesday, dragged down by energy shares. Financials weighed on the blue-chip index on Wednesday. Ultimately, strong ADP data helped the index register its first session of gains for the week on Thursday.

Last Week’s Performance

Markets were closed on Monday for the Memorial Day holiday. On Tuesday, the index declined 0.2%, dragged down primarily by energy shares. Investors expressed doubts about whether OPEC and non-OPEC players including Russia will be able to implement an effective production cut policy to stabilize the global crude market.

As per the Federal Reserve’s Beige Book, the U.S. economy expanded at a “modest or moderate” pace through late May and is still growing at the same pace. Meanwhile, pending home sales in April tumbled for the second month in a row.

Over last month, the Dow advanced 0.5%. Even as FOMC minutes and Trump’s budget proposals were released, the President’s decision to dismiss of FBI director James Comey sent ripples through the market. Meanwhile, U.S. auto industry reported disappointing sales in April, with sales hitting 16.88 million, below an expected annual rate of 17.2 million.

The index advanced 0.7% on Thursday, buoyed by solid private sector hiring. According to ADP data released on Thursday, private payrolls surged by 253,000 in May which came in above its consensus estimate of 185,000. The ISM Manufacturing index increased from 54.8 in April to 54.9 for May. However, construction spending declined by 1.4% while auto sales experienced a year-over-year decline to come in at 16.7 million.

Components Moving the Index

General Electric Company (NYSE:GE – Free Report ) recently inked various agreements for power generation, aircraft engines, and services in Vietnam as the country attempts to forge strong business ties with the U.S. amid growing concerns about China’s meteoric rise. The agreements worth $5.8 billion is General Electric’s biggest such deals to date with any Southeast Asian country.

The company signed a memorandum of understanding (MoU) to co-develop two 750-megawatt gas-fueled turbine power plants in the country along with a joint development agreement for an 800-megawatt Phu Cuong Wind Farm in Soc Trang. These deals, worth $2 billion, will support the development of Vietnam’s energy sectors.

In addition, Zacks Rank #3 (Hold) rated General Electric signed agreements valued at over $3.58 billion for new aircraft engines and maintenance support. These include deals for 20 jet engines for Vietjet Aviation, a low-cost airline of the country. (Read: GE Inks $5.58B Deals in Vietnam to Augment Regional Ties )

The Walt Disney Company ’s (NYSE:DIS – Free Report ) superb box office run continues with "Pirates of the Caribbean: Dead Men Tell No Tales," topping the Memorial Day weekend box office collections. During the four day holiday weekend, the movie garnered nearly $77 million domestically beating Dwayne Johnson starrer "Baywatch." In the first three days, the movie collected $62.2 million. Disney has a Zacks Rank #3.

However, the opening weekend collections for the “Pirates of the Caribbean” were well below the previous three movies of the franchise. In 2011, “Pirates of the Caribbean: On Stranger Tides” collected $90 million domestically in the opening weekend, while in 2007 “Pirates of the Caribbean: At World's End” garnered a whopping $153 million over the Memorial Day weekend. In 2006, “Pirates of the Caribbean: Dead Man's Chest” collected $135 million over the opening weekend. (Read: Disney's Pirates of the Caribbean Sequel Tops Box Office )

Merck & Co., Inc. (NYSE:MRK – Free Report ) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.

Merck sees potential in the development and commercialization of the candidate for the treatment of Alzheimer’s disease (AD) and other neurological diseases. The company will make an undisclosed upfront payment to Teijin Pharma, which is also eligible to receive development, regulatory and sales milestone payments. Further, Teijin Pharma will receive royalties on product sales and retains an option to co-promote an approved product in Japan. (Read: Merck Buys Rights to Anti-tau Antibody for Alzheimer )

In a separate development, Merck announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies. The drug is meant for the treatment of adults and pediatric patients with HIV-1 infection (weighing at least 40 kg). The stock has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Pfizer, Inc. (NYSE:PFE – Free Report ) announced that an FDA advisory committee has recommended approval of its biosimilar version of Amgen's erythropoiesis-stimulating agent (ESA) Epogen and Procrit.

The Oncologic Drugs Advisory Committee (ODAC) recommended approval across all indications of the reference product, which includes treatment of anemia and chronic kidney disease (CKD). (Read: Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote )

In a separate development, Zacks Rank #3-rated Pfizer announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB). (Read: Pfizer's Trumenba Vaccine Approved by European Commission )

Chevron (NYSE:CVX – Free Report ) recently inked a $250 million deal with Royal Dutch Shell plc (RDS.A) per which the latter will acquire most of the Chevron’s gas-related assets in the Republic of Trinidad and Tobago. This development will substantially increase Royal Dutch Shell’s natural gas-rich holdings in the twin-island Caribbean nation.

Per the deal, Shell will buy all the shares of Zacks Rank #3-rated Chevron’s local subsidiary, Chevron Trinidad and Tobago Resources SRL, including 50% stake in three offshore natural gas fields in the East coast Marine Area. Shell will also acquire part of Chevron’s stake in the Manatee cross-border gas field shared with neighboring Venezuela. Furthermore, Shell will purchase Chevron’s entire stake in Trinling Ltd LNG transportation and marketing company. (Read: Shell Inks Deal with Chevron to Expand Holdings in Trinidad )

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on GE - FREE

Get the full Report on DIS - FREE

Get the full Report on MRK - FREE

Get the full Report on PFE - FREE

Get the full Report on CVX - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Click for Free General Electric Company (GE) Stock Analysis Report >>
 
Click for Free Walt Disney Company (The) (DIS) Stock Analysis Report >>
 
Click for Free Merck & Company, Inc. (MRK) Stock Analysis Report >>
 
Click for Free Pfizer, Inc. (PFE) Stock Analysis Report >>
 
Click for Free Chevron Corporation (CVX) Stock Analysis Report >>
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement